Discovery of ICOS‐Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening
ChemMedChem · 2024-11-18 · 19 (22)
DOI: 10.1002/cmdc.202400545 ↗At a glance
Journal article in ChemMedChem, published online on 2024-10-22. Written by Longfei Zhang and 4 co-authors. Institution: Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY, 10065, USA. Major MEDLINE topics: Inducible T-Cell Co-Stimulator Protein, Mass Spectrometry, Small Molecule Libraries. Cited 31 times so far (Crossref); 38 references. The full text is freely available in PubMed Central. Funded by: Generalitat Valenciana, NIH HHS, Spanish Ministerio de Ciencia, Innovación y Universidades.
Abstract (original language)
Inducible T cell co‐stimulator (ICOS) is a positive immune checkpoint receptor expressed on the surface of activated T cells, which could promote cell function after being stimulated with ICOS ligand (ICOS−L). Although clinical benefits have been reported in the ICOS modulation‐based treatment for cancer and autoimmune disease, current modulators are restricted in biologics, whereas ICOS‐targeted small molecules are lacking. To fill this gap, we performed an affinity selection mass spectrometry (ASMS) screening for ICOS binding using a library of 15,600 molecules. To the best of our knowledge, this is the first study that utilizes ASMS screening to discover small molecules targeting immune checkpoints. Compound 9 with a promising ICOS/ICOS−L inhibitory profile (IC 50 =29.38±3.41 μM) was selected as the template for the modification. Following preliminary structure‐activity relationship (SAR) study and molecular dynamic (MD) simulation revealed the critical role of the ortho‐hydroxy group on compound 9 in the ICOS binding, as it could stabilize the interaction via the hydrogen bond formation with residuals on the glycan, and the depletion could lead to an activity lost. This work validates a promising inhibitor for the ICOS/ICOS−L interaction, and we anticipate future modifications could provide more potent modulators for this interaction.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY, 10065, USA.
- BioComp group, Institute of Advanced Materials (INAM), Universitat Jaume I, Castellon, Spain.
ORCID profiles: Moustafa T Gabr
Funding
- Generalitat Valenciana
- NIH HHS
- Spanish Ministerio de Ciencia, Innovación y Universidades
- NIDDK NIH HHS
- National Institutes of Health
Cite
APA
Zhang, L., Calvo-Barreiro, L., de Sousa Batista, V., Świderek, K., & Gabr, M. T. (2024). Discovery of ICOS‐Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening. ChemMedChem, 19(22). https://doi.org/10.1002/cmdc.202400545
Vancouver
Zhang L, Calvo-Barreiro L, de Sousa Batista V, Świderek K, Gabr MT. Discovery of ICOS‐Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening. ChemMedChem. 2024;19(22). doi:10.1002/cmdc.202400545
BibTeX
@article{Zhang2024,
author = {Zhang, Longfei and Calvo-Barreiro, Laura and de Sousa Batista, Victor and Świderek, Katarzyna and Gabr, Moustafa T},
title = {Discovery of ICOS‐Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening},
journal = {ChemMedChem},
year = {2024},
volume = {19},
number = {22},
doi = {10.1002/cmdc.202400545}
}
EUVIMED